促性腺激素释放激素激动剂联合米非司酮治疗子宫内膜异位症的临床疗效

Clinical efficacy of gonadotropin-releasing hormone agonists combined with mifepristone in the treatment of endometriosis

目的探究促性腺激素释放激素激动剂(GnRH-a)联合米非司酮治疗子宫内膜异位症的临床疗效。方法选取2019年2月至2021年4月本院收治的84例子宫内膜异位症患者作为研究对象,按照随机数字表法分为对照组与观察组,每组42例。对照组采用米非司酮治疗,观察组采用GnRH-a联合米非司酮治疗。比较两组临床疗效、激素水平、子宫内膜厚度及不良反应发生情况。结果观察组治疗总有效率为97.62%,高于对照组的80.95%,差异有统计学意义(P<0.05)。干预前,两组促卵泡激素(FSH)、促黄体生成素(LH)、雌二醇(E_(2))水平比较差异无统计学意义;干预后,两组FSH、LH、E_(2)水平均低于干预前,且观察组低于对照组,差异有统计学意义(P<0.05)。干预前,两组子宫内膜厚度比较差异无统计学意义;干预后,两组子宫内膜厚度均薄于干预前,且观察组薄于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为2.38%,低于对照组的19.05%,差异有统计学意义(P<0.05)。结论GnRH-a联合米非司酮治疗子宫内膜异位症效果显著,可改善患者生殖激素水平,降低不良反应发生率,值得临床推广应用。

Objective To investigate the clinical efficacy of gonadotropin-releasing hormone agonist(GnRH-a)combined with mifepristone in the treatment of endometriosis.Methods 84 patients with endometriosis admitted to our hospital from February 2019 to April 2021 were selected as the study subjects,and they were randomly divided into the control group and the observation group according to random number table method,with 42 cases in each group.The control group was treated with mifepristone,while the observation group was treated with GnRH-a combined with mifepristone,the clinical efficacy,hormone levels,endometrial thickness and incidence of adverse reactions were compared between the two groups.Results The total effective rate in the observation group was 97.62%,which was higher than 80.95%in the control group,the difference was statistically significant(P<0.05).Before intervention,there were no statistically significant differences in the levels of follicle-stimulating hormone(FSH),luteinizing hormone(LH),estradiol(E_(2))between the two groups;after intervention,the levels of FSH,LH,and E_(2) of the two groups were lower than before intervention,and the observation group was lower than the control group,and the differences were statistically significant(P<0.05).Before intervention,there were no statistically significant differences in endometrial thickness between the two groups;after intervention,the endometrial thickness of the two groups were thinner than before intervention,and the observation group was thinner than the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 2.38%,which was lower than 19.05%in the control group,the difference was statistically significant(P<0.05).Conclusion The gonadotropin-releasing hormone agonists combined with mifepristone has significant therapeutic effect on endometriosis,which can improve patients'reproductive hormone levels and reduce the incidence of adverse reactions,which is worthy of clinical promotion and application.